Schrödinger develops an industry-leading computational platform that integrates physics-based molecular simulations and machine learning to expand exploration of chemical space for drug discovery and materials design. The company licenses this platform to pharmaceutical, biotechnology, chemical, and electronics companies and has built a robust pipeline of therapeutic assets held both internally and in partnerships. Its collaborations have contributed to two FDA-approved oncology drugs, several clinical-stage assets, and more than two dozen additional programs moving through discovery and development. Schrödinger also co-founded companies including Nimbus Therapeutics and Morphic Therapeutic and continues significant investment in basic research. The company announced a $110 million financing to support advancement of its wholly-owned drug discovery pipeline, expansion of collaborations with biopharma worldwide, and continued R&D to extend its proprietary platform. Founded in 1990, Schrödinger has nearly 400 employees in its New York City headquarters and around the world. Schrödinger, Inc. is a New York–based company that provides chemical simulation software and services for pharmaceutical and biotechnology research. Its core capabilities center on computer-aided drug design and computational chemistry. The company announced an investment from Cascade Investment, L.L.C., the private vehicle wholly owned by William H. Gates III. Management said the funding is intended to enable a number of research and development projects aimed at making considerable improvements in the state of the art in computer-aided drug design. Company leadership described the investment as both an important validation and a significant opportunity for Schrödinger. Founders and advisers highlighted Cascade’s interest in applying computational technologies to pharmaceutical research and ultimately developing treatments for a wide range of diseases.

Total raised

$110M

Funding rounds

2

Latest round

Equity

Latest activity

May 2019